Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension

被引:1
|
作者
Zhang, Chang [1 ]
Tsang, Yuen [2 ]
He, Jinghua [3 ]
Panjabi, Sumeet [2 ]
机构
[1] Janssen Business Technol Commercial Data Sci, Titusville, NJ USA
[2] Janssen Sci Affairs LLC, Real World Value & Evidence, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
[3] Janssen Sci Affairs LLC, Real World Res, Titusville, NJ USA
关键词
Hospitalization; Healthcare resource utilization; Predictive risk factors; Patient characteristics; Pulmonary arterial hypertension; SCORE CALCULATOR; SURVIVAL; REGISTRY; MANAGEMENT; OUTCOMES; COSTS;
D O I
10.1007/s12325-023-02501-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
IntroductionUS claims-based analyses emphasize the substantial hospitalization burden of patients with pulmonary arterial hypertension (PAH) and the significant need for improved monitoring and more timely interventions. A claims-based predictive model may be useful to assist healthcare providers and payers in identifying patients with PAH at increased hospitalization risk. To address this aim, we constructed statistical models using baseline patient variables available in administrative healthcare claims to predict patients' risk for all-cause and PH-related hospitalization within 1 year of initiating >= 1 PAH indicated medication.MethodsAdult patients with PAH who newly initiated >= 1 PAH indicated medication were selected from the MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-January 31, 2019). Cox regression models were built with a randomly selected training set and evaluated using a validation set of remaining patients. Predictive variables for the models were selected in three steps: clinical knowledge, univariate analysis, and backward stepwise selection.ResultsWithin 1 year of initiating >= 1 PAH indicated medication, 1502/3872 (38.8%) had an all-cause hospitalization and 950/3872 (24.5%) had a pulmonary hypertension (PH)-related hospitalization. Predictive risk factors for all-cause hospitalization were Quan-Charlson Comorbidity Index (CCI) score 2-3 [hazard ratio (HR) 1.229; P = 0.038] and >= 4 (HR 1.531; P < 0.001), claims-based frailty index (CFI) score > 1 (highest frailty level; HR 1.301; P = 0.018), hemoptysis (HR 1.254; P = 0.016), malaise/fatigue (HR 1.150; P = 0.037), history of PH-related hospitalization (HR 1.171; P = 0.011), non-PH-related ER visit (HR 1.713; P = 0.014), and higher non-PH-related outpatient visit cost (HR 1.069; P < 0.001). Predictive risk factors for PH-related hospitalization were female sex (HR 1.264; P = 0.004), Quan-CCI score >= 4 (HR 1.408; P = 0.008), portal hypertension (HR 1.565; P = 0.019), CFI score > 1 (HR 1.522; P = 0.002), dyspnea (HR 1.259; P = 0.023), and history of PH-related hospitalization (HR 1.273; P = 0.002).ConclusionsThe US claims-based predictive models showed acceptable performance to predict 1-year hospitalization among patients with PAH.
引用
收藏
页码:2481 / 2492
页数:12
相关论文
共 50 条
  • [31] Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
    Tsang, Yuen
    Singh, Risho
    Verma, Sumit
    Panjabi, Sumeet
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 741 - 756
  • [32] Practical management of riociguat in patients with pulmonary arterial hypertension
    Halank, Michael
    Tausche, Kristin
    Gruenig, Ekkehard
    Ewert, Ralf
    Preston, Ioana R.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [33] Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
    Yuen Tsang
    Risho Singh
    Sumit Verma
    Sumeet Panjabi
    Rheumatology and Therapy, 2023, 10 : 741 - 756
  • [34] Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors
    Charalampopoulos, Athanasios
    Howard, Luke S.
    Tzoulaki, Ioanna
    Gin-Sing, Wendy
    Grapsa, Julia
    Wilkins, Martin R.
    Davies, Rachel J.
    Nihoyannopoulos, Petros
    Connolly, Susan B.
    Gibbs, J. Simon R.
    PULMONARY CIRCULATION, 2014, 4 (04) : 669 - 678
  • [35] A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension
    Xiong, Wei
    Zhao, Yunfeng
    Xu, Mei
    Pudasaini, Bigyan
    Guo, Xuejun
    Liu, Jinming
    BMC PULMONARY MEDICINE, 2018, 18
  • [36] Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension A 1-Year, Prospective, Open-Label Observation of Outcome and Survival
    Benza, Raymond L.
    Barst, Robyn J.
    Galie, Nazzareno
    Frost, Adaani
    Girgis, Reda E.
    Highland, Kristin B.
    Strange, Charlie
    Black, Carol M.
    Badesch, David B.
    Rubin, Lewis
    Fleming, Thomas R.
    Naeije, Robert
    CHEST, 2008, 134 (04) : 775 - 782
  • [37] Prognosis in children with pulmonary arterial hypertension: 10-year single-centre experience
    Zuk, Malgorzata
    Mazurkiewicz-Anton, Katarzyna
    Migdal, Anna
    Jagiellowicz-Kowalska, Dorota
    Turska-Kmiec, Anna
    Ziolkowska, Lidia
    Brzezinska-Rajszys, Grazyna
    Zubrzycka, Maria
    Kawalec, Wanda
    KARDIOLOGIA POLSKA, 2016, 74 (02) : 159 - 167
  • [38] Pulmonary arterial hypertension: tailoring treatment to risk in the current era
    Gaine, Sean
    McLaughlin, Vallerie
    EUROPEAN RESPIRATORY REVIEW, 2017, 26 (146)
  • [39] A simple discharge risk model for predicting 1-year mortality in hospitalised acute decompansated heart failure patients with reduced ejection fraction
    Karauzum, Kurtulus
    Karauzum, Irem
    Ural, Dilek
    Baydemir, Canan
    Aktas, Mujdat
    Celikyurt, Umut
    Kozdag, Guliz
    Argan, Onur
    Bozyel, Serdar
    Agir, Aysen
    ACTA CARDIOLOGICA, 2018, 73 (02) : 164 - 170
  • [40] Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    Benza, Raymond L.
    Miller, Dave P.
    Gomberg-Maitland, Mardi
    Frantz, Robert P.
    Foreman, Aimee J.
    Coffey, Christopher S.
    Frost, Adaani
    Barst, Robyn J.
    Badesch, David B.
    Elliott, C. Gregory
    Liou, Theodore G.
    McGoon, Michael D.
    CIRCULATION, 2010, 122 (02) : 164 - U138